Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Astellas Pharma Inc Astellas Pharma US, Inc. |
---|---|
Information provided by: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00293891 |
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: Tacrolimus Cream |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | J. Rico, MD | Astellas Pharma US, Inc. |
Study ID Numbers: | 04-0-206 |
Study First Received: | February 16, 2006 |
Last Updated: | December 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00293891 History of Changes |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Treatment Outcome Tacrolimus Safety Psoriasis |
Immunologic Factors Skin Diseases Psoriasis |
Tacrolimus Immunosuppressive Agents Skin Diseases, Papulosquamous |
Immunologic Factors Skin Diseases Psoriasis Physiological Effects of Drugs |
Tacrolimus Immunosuppressive Agents Skin Diseases, Papulosquamous Pharmacologic Actions |